Skip to main content

. 1987 May 16;294(6582):1260. doi: 10.1136/bmj.294.6582.1260

Controlled trial of gamma linolenic acid in Duke's C colorectal cancer.

M B McIllmurray, W Turkie

PMCID: PMC1246429 PMID: 3036291

1260

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Booyens J., Dippenaar N., Fabbri D., Engelbrecht P., Katzeff I. E. The effect of gamma-linolenic acid on the growth of human osteogenic sarcoma and oesophageal carcinoma cells in culture. S Afr Med J. 1984 Feb 18;65(7):240–242. [PubMed] [Google Scholar]
Dippenaar N., Booyens J., Fabbri D., Engelbrecht P., Katzeff I. E. The reversibility of cancer: evidence that malignancy in human hepatoma cells is gamma-linolenic acid deficiency-dependent. S Afr Med J. 1982 Oct 30;62(19):683–685. [PubMed] [Google Scholar]
Dippenaar N., Booyens J., Fabbri D., Katzeff I. E. The reversibility of cancer: evidence that malignancy in melanoma cells is gamma-linolenic acid deficiency-dependent. S Afr Med J. 1982 Oct 2;62(15):505–509. [PubMed] [Google Scholar]
Horrobin D. F. The reversibility of cancer: the relevance of cyclic AMP, calcium, essential fatty acids and prostaglandin E1. Med Hypotheses. 1980 May;6(5):469–486. doi: 10.1016/0306-9877(80)90099-7. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES